2008 Annual
Stockholders Meeting
May 20, 2008
Financial Highlights
0.52
0.75
Diluted Earnings Per Share
4,548
6,690
Net Income
8,201
10,016
Income from Operations
31,005
36,356
Gross Profit
$69,804
$80,285
Revenues
2006
2007
in thousands, except for per share
amounts
Revenue Growth
Compound average growth rate 12%
Gross Margin
Operating Margin
Operating Income
Diluted Earnings Per Share
Cash Flows
Financial Ratios
Period Ending:
12/31/2007
12/31/2006
12/31/2005
12/31/2004
12/31/2003
Current Ratio
197%
210%
196%
124%
111%
Quick Ratio
163%
156%
144%
83%
75%
Cash Ratio
19%
14%
15%
2%
5%
Pre-Tax Margin
12%
10%
7%
5%
-1%
Profit Margin
8%
7%
5%
3%
-1%
Pre-Tax ROE
17%
15%
9%
8%
-1%
After Tax ROE
12%
9%
7%
5%
-1%
Operating Expenses as a
Percent of Sales
32.8%
32.7%
34.3%
34.4%
36.2%
Liquidity Ratios
Profitability Ratios
MEDTOX Scientific, Inc.
Building For The Future!
Background
MEDTOX: Drug Testing Industry Leader
Late 1990’s:
Began developing Clinical Lab capabilities
Early 2000’s:
Introduced Clinical Trial Services
2007:
Continued Clinical Laboratory expansion
MEDTOX Total Revenue
Areas of Clinical Expansion
Areas of Clinical Expansion
Regional Clinical Laboratory
Offering lab services for physician market
Accessible regional market = $200 MM+ revenue
Areas of laboratory specialty
Anatomic Pathology & Cytology
Microbiology
Molecular diagnostics
Comprehensive clinical chemistry
Hematology
Immunology
Areas of Clinical Expansion
Pain Management
70 MM+ Americans suffer from chronic pain
Management of pain is a growing industry
ToxAssure® Program: Pain Patient Monitoring
Targeted Market Segments
Pain clinics
Hospitals
Family practice
Other medical practices
Areas of Clinical Expansion
Clinical Trials Services
Current Areas of Focus
Bio-Analytical Services & Assay Development
Central Laboratory Services
New Opportunities – New Clinical Laboratory
Flow Cytometry
Anatomic Pathology/Cytology
Molecular Diagnostics/Pathology
Microbiology
Expanded Biomarkers
Shareholder Benefits
Exciting new revenue opportunities
Continued laboratory diversification
Less exposure to economic downturns
Platform to participate in new clinical areas
Expanded capabilities extend to multiple
markets
RCL scalable to new geographic markets
2008 Annual
Stockholders Meeting
May 20, 2008